ACTRN12618001998235已完成1 期
Randomized, Single Dose, Three-way Crossover Open Label Pharmacokinetic Parameters Study of AFT Maxigesic IV (Acetaminophen 1000mg + Ibuprofen 300mg/100 mL solution for infusion), Infusion over 15 minutes (One Dose Only), Ultracet (Acetaminophen 325mg + tramadol 37.5mg) Tablets and Dr. Reddy Laboratories Ibuprofen Tablets (Ibuprofen 800mg), after Oral administration to 30 healthy volunteers under fasting conditions
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- All
入选标准
- •Healthy male and female volunteers aged 18 to 50 years of age. Females must be sterile or using adequate contraception. Participants must not have taken any prescription medications for at least 14 days or over-the-counter medications and herbal remedies for at least 7 days before the start of each study phase and for the duration of the study, with the exception of oral contraceptives and the study medication.
排除标准
- •Female who are pregnant or nursing (not applicable for male subjects).
- •Female of childbearing potential who are unwilling to take adequate contraceptive precautions, i.e., a hormonal contraceptive, an intrauterine device, double-barrier method, or abstinence. A woman of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone a partial or total hysterectomy or surgical sterilisation, e.g. bilateral tubal ligation, bilateral oophorectomy (not applicable for male subjects).
- •Female of childbearing potential who are unwilling to undergo a urine pregnancy test (not applicable for male subjects).
- •Have an alcohol intake in excess of 14 units per week for females and 21 units per week for males.
- •Have a history of drug abuse or positive test results for drug abuse during screening.
- •Unwilling to abstain from smoking throughout the whole duration of the study
- •Unable and refuse to abstain the used prescription drugs (not including oral contraceptives and the study medication) within 14 days prior to study drug administration or have used over-the-counter drugs or herbal products within 7 days prior to study drug administration and during the study.
- •Unable and refuse to abstain the use of vitamins for nutritional purposes within
- •2 days prior to study drug administration until the last study sample is collected in each period.
- •Unable and refuse to abstain to consume grapefruit containing foods or beverages within 7 days or caffeine containing foods or beverages within 24 hours prior to study drug administration until the last study sample is collected in each period.
- •Currently, or in last 80 days, participating in a clinical trial involving another study drug.
- •Have donated blood or blood products within 60 days prior to study drug administration.
- •Have a clinically significant abnormal laboratory test (as determined by the Principal Investigator), Hb, PCV and RBC indices (MCV, MCH and MCHC) tests which deviated outside the 5% of reference range or laboratory results of liver or kidney function tests (creatinine, urea and ALP will be accepted if below reference range, total protein and albumin accepted if above reference range) are outside the reference range.
- •Be on a special diet (for example is vegetarian).
- •Unable and refuse to abstain to engage in strenuous exercise within 24 hours prior to study drug administration until the last sample is collected in each study period.
- •Have at screening examination a pulse outside the normal range of (60-100 beat per minute) or a body temperature outside the normal range of (35.0-37.2 Degrees Celsius ) or a respiratory rate outside the normal range of (14-20 breath per minute) or a sitting blood pressure less than 100/60 mm Hg or more than or equal to 140/90 mm Hg.
- •Unable and refuse to abstain to consume any beverages or food containing alcohol for at least 24 hours prior to study drug administration until the last study sample is collected in each period.
- •Have a history of difficulties in swallowing or any gastrointestinal disease which could affect the drug absorption.
- •Suffering from any other diseases or condition which, in the opinion of the investigator, means that it would not be in the participant’s best interests to participate in this study.
- •Subject is a heavy smoker (more than 10 cigarettes per day).
- •Acute infection within one week preceding study drug administration.
- •Have any history of
研究者
相似试验
已完成
1 期
A pharmacokinetic study of acetaminophen, ibuprofen, and diphenhydramine hydrochloride in healthy volunteers under fasting conditions.ACTRN12621001542886AFT Pharmaceuticals Ltd30
已完成
1 期
A pharmacokinetic study of acetaminophen, ibuprofen, and xylometazoline hydrochloride in healthy volunteers under fasting conditions.ACTRN12621001055897AFT Pharmaceuticals Ltd30
已完成
1 期
Pharmacokinetic study of two orally formulated modified release tablets of Ferrous Sulfate 325mg and Sodium Ascorbate 562.4 mg in healthy volunteers under fasting and fed conditions.AnaemiaBlood - AnaemiaACTRN12619000171112AFT Pharmaceuticals Ltd.25
已完成
不适用
Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mgDiseases of the musculo-skeletal system and connective tissueKCT0000701Hanmi Pharm68
进行中（未招募）
不适用
Drug-drug Interaction between aceclofenac 200 mg and esomeprazole 20 mg in healthy volunteersKCT0002341Chonbuk National University Hospital30